Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
|
9 Months Ended |
Dec. 31, 2021 |
|---|
| Share-based Payment Arrangement [Abstract] |
|
| Schedule of stock based compensation expenses |
| |
|
Nine months ended |
|
|
Fiscal year ended |
|
| |
|
December 31,
2021 |
|
|
March 31,
2021 |
|
| Research and development expenses |
|
$ |
384 |
|
|
$ |
2,444 |
|
| Selling, general and administrative expenses |
|
|
8,318 |
|
|
|
11,987 |
|
| Total stock-based compensation |
|
$ |
8,702 |
|
|
$ |
14,431 |
|
|
| Schedule of restricted stock awards |
| |
|
Number of Shares |
|
|
Weighted Average
Grant-Date
Fair Value
|
|
| Unvested at March 31, 2021 |
|
|
1,061,905 |
|
|
$ |
4.50 |
|
| Granted |
|
|
1,200,000 |
|
|
$ |
1.33 |
|
| Vested |
|
|
(322,222 |
) |
|
$ |
1.24 |
|
| Unvested at December 31, 2021 |
|
|
1,939,683 |
|
|
$ |
3.08 |
|
| |
|
Number of Shares |
|
|
Weighted Average
Grant-Date
Fair Value
|
|
| Unvested at March 31, 2021 |
|
|
777,778 |
|
|
$ |
5.12 |
|
| Vested |
|
|
(66,666 |
) |
|
$ |
5.12 |
|
| Canceled |
|
|
(711,112 |
) |
|
$ |
5.12 |
|
| Unvested at December 31, 2021 |
|
|
- |
|
|
$ |
-
|
|
|
| Schedule of of stock options granted |
| |
|
Nine months
ended |
|
|
Fiscal year
ended |
|
| |
|
December 31,
2021 |
|
|
March 31,
2021 |
|
| Dividend yield |
|
|
0 |
% |
|
|
0 |
% |
| Expected price volatility |
|
|
50% - 103 |
% |
|
|
50 |
% |
| Risk free interest rate |
|
|
0.35% - 1.33 |
% |
|
|
0.16% - 0.94 |
% |
| Expected term |
|
|
3-7 years |
|
|
|
1-7 years |
|
|
| Schedule of stock options |
| |
|
Shares Underlying
Options |
|
|
Weighted Average
Exercise Price |
|
|
Weighted Average
Remaining
Contractual
Term (Years) |
|
|
Aggregate Intrinsic
Value |
|
| Outstanding at March 31, 2021 |
|
|
10,928,607 |
* |
|
$ |
2.73 |
|
|
|
8.2 |
|
|
$ |
17,524 |
|
| Granted |
|
|
1,442,204 |
|
|
$ |
3.53 |
|
|
|
9.8 |
|
|
|
|
|
| Exercised |
|
|
(419,000 |
) |
|
$ |
0.51 |
|
|
|
- |
|
|
|
|
|
| Canceled |
|
|
(816,379 |
) |
|
$ |
3.88 |
|
|
|
- |
|
|
|
|
|
| Outstanding at December 31, 2021 |
|
|
11,135,432 |
|
|
$ |
2.85 |
|
|
|
7.6 |
|
|
$ |
13,031 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2021 |
|
|
9,850,155 |
|
|
$ |
2.75 |
|
|
|
7.4 |
|
|
$ |
12,402 |
|
|
| Schedule of warrant activity |
| |
|
Shares Underlying
Warrants |
|
|
Weighted Average
Exercise Price |
|
|
Weighted Average
Remaining
Contractual
Term (Years) |
|
|
Aggregate Intrinsic
Value |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at March 31, 2021 |
|
|
3,883,083 |
|
|
$ |
2.49 |
|
|
|
4.6 |
|
|
$ |
7,763 |
|
| Issued |
|
|
775,724 |
|
|
$ |
3.94 |
|
|
|
4.8 |
|
|
|
|
|
| Canceled |
|
|
(133,630 |
) |
|
$ |
5.63 |
|
|
|
- |
|
|
|
|
|
| Outstanding at December 31, 2021 |
|
|
4,525,177 |
|
|
$ |
2.65 |
|
|
|
4.0 |
|
|
$ |
7,088 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2021 |
|
|
3,468,422 |
|
|
$ |
1.95 |
|
|
|
3.8 |
|
|
$ |
6,751 |
|
|
| Schedule of estimated the fair value of the warrants |
| |
|
Nine
months ended
December 31,
2021 |
|
|
Fiscal
year ended
March 31,
2021 |
|
| |
|
|
|
|
|
|
| Expected price volatility |
|
|
50% - 103% |
|
|
|
50.0%
|
|
| Risk free interest rate |
|
|
0.81% - 1.2%
|
|
|
|
0.4% - 2.4%
|
|
| Expected term |
|
|
5 years |
|
|
|
5 years |
|
|